Jazz Pharmaceuticals plc (JAZZ)
Every FINRA and SEC series the site collects for Jazz Pharmaceuticals plc: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.6M
Short interest
settlement 2026-08-14
3.8
Days to cover
+7.7% vs prior
60.8%
Short share of volume
2026-09-11
344
Fails to deliver
settlement 2026-08-12
-$22.2M
Insider flow, 90 days
0 buys, 8 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in JAZZ is 3,614,639 shares, down 187,224 shares over the last month. Over the last 48 readings it ranged from 1,892,100 shares (30 August 2024) to 6,526,407 shares (31 March 2026). At the reported average volume of 950K shares a day that is 3.8 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/jazz" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 3,614,639 | +7.7% | 949,549 | 3.81 |
| 2026-07-31 | 3,355,182 | -11.8% | 629,781 | 5.33 |
| 2026-07-15 | 3,801,863 | +8.6% | 786,595 | 4.83 |
| 2026-06-30 | 3,500,138 | -11.2% | 932,540 | 3.75 |
| 2026-06-15 | 3,941,396 | -8.1% | 930,091 | 4.24 |
| 2026-05-29 | 4,290,867 | -11.5% | 842,467 | 5.09 |
| 2026-05-15 | 4,849,332 | -4.7% | 1,033,745 | 4.69 |
| 2026-04-30 | 5,090,611 | -2.9% | 955,432 | 5.33 |
| 2026-04-15 | 5,240,459 | -19.7% | 878,015 | 5.97 |
| 2026-03-31 | 6,526,407 | +5.9% | 816,466 | 7.99 |
| 2026-03-13 | 6,164,020 | +2.8% | 807,327 | 7.64 |
| 2026-02-27 | 5,997,312 | -0.8% | 1,327,203 | 4.52 |
| 2026-02-13 | 6,044,810 | +6.7% | 661,078 | 9.14 |
| 2026-01-30 | 5,663,941 | +5.8% | 894,750 | 6.33 |
| 2026-01-15 | 5,352,497 | -0.2% | 1,494,594 | 3.58 |
| 2025-12-31 | 5,363,382 | +6.4% | 789,274 | 6.80 |
| 2025-12-15 | 5,042,462 | +1.4% | 1,068,294 | 4.72 |
| 2025-11-28 | 4,974,908 | +2.8% | 2,218,942 | 2.24 |
| 2025-11-14 | 4,839,654 | -5.4% | 913,024 | 5.30 |
| 2025-10-31 | 5,116,514 | +9.1% | 612,383 | 8.36 |
| 2025-10-15 | 4,689,812 | -0.8% | 702,004 | 6.68 |
| 2025-09-30 | 4,729,765 | -10.8% | 727,488 | 6.50 |
| 2025-09-15 | 5,302,576 | -7.2% | 681,644 | 7.78 |
| 2025-08-29 | 5,714,048 | +1.6% | 735,444 | 7.77 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of JAZZ volume is 60.8%, up 10.4 points over the last five sessions. Over the last 52 readings it ranged from 32.4% (14 July 2026) to 92.0% (27 August 2026). The latest reading is 4.3 points below the 30-session average of 65.1%, on 204K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 124K | 204K | 60.8% | 3,652 |
| 2026-09-10 | 243K | 335K | 72.5% | 220 |
| 2026-09-09 | 100K | 172K | 58.2% | 173 |
| 2026-09-08 | 83K | 159K | 52.5% | 18 |
| 2026-09-04 | 83K | 135K | 61.1% | 6,575 |
| 2026-09-03 | 115K | 228K | 50.3% | 14,500 |
| 2026-09-02 | 401K | 557K | 72.0% | 32,324 |
| 2026-09-01 | 437K | 567K | 77.1% | 30,210 |
| 2026-08-31 | 389K | 505K | 77.0% | 276 |
| 2026-08-28 | 733K | 832K | 88.1% | 29,134 |
| 2026-08-27 | 2.8M | 3.1M | 92.0% | 25,225 |
| 2026-08-26 | 1.0M | 1.2M | 86.1% | 90,164 |
| 2026-08-25 | 560K | 696K | 80.5% | 0 |
| 2026-08-24 | 110K | 150K | 73.2% | 14,500 |
| 2026-08-21 | 147K | 214K | 68.7% | 690 |
| 2026-08-20 | 97K | 183K | 53.4% | 0 |
| 2026-08-19 | 131K | 207K | 63.3% | 0 |
| 2026-08-18 | 131K | 215K | 60.8% | 0 |
| 2026-08-17 | 107K | 189K | 56.5% | 822 |
| 2026-08-14 | 103K | 239K | 43.0% | 0 |
| 2026-08-13 | 127K | 204K | 62.3% | 122 |
| 2026-08-12 | 148K | 236K | 62.5% | 2,503 |
| 2026-08-11 | 502K | 630K | 79.6% | 0 |
| 2026-08-10 | 225K | 420K | 53.5% | 0 |
| 2026-08-07 | 132K | 333K | 39.8% | 740 |
| 2026-08-06 | 285K | 371K | 76.9% | 16 |
| 2026-08-05 | 185K | 278K | 66.6% | 195 |
| 2026-08-04 | 405K | 942K | 43.0% | 0 |
| 2026-08-03 | 391K | 603K | 64.8% | 0 |
| 2026-07-31 | 137K | 242K | 56.6% | 325 |
Fails to deliver
SEC, by settlement date. JSONAs of 12 August 2026, the fails-to-deliver balance in JAZZ is 344 shares, down 24,375 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (28 November 2025) to 24,719 shares (7 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-12 | 344 | $247.98 | $85K |
| 2026-08-07 | 24,719 | $256.65 | $6.3M |
| 2026-08-04 | 91 | $251.58 | $23K |
| 2026-07-31 | 14,671 | $258.38 | $3.8M |
| 2026-07-30 | 14,696 | $255.97 | $3.8M |
| 2026-07-29 | 14,699 | $256.92 | $3.8M |
| 2026-07-28 | 377 | $255.43 | $96K |
| 2026-07-20 | 31 | $247.53 | $8K |
| 2026-07-07 | 274 | $244.17 | $67K |
| 2026-06-30 | 6 | $237.72 | $1K |
| 2026-06-29 | 2,167 | $230.02 | $498K |
| 2026-06-22 | 9,049 | $224.66 | $2.0M |
| 2026-06-15 | 2 | $230.56 | $461 |
| 2026-06-05 | 575 | $240.06 | $138K |
| 2026-06-02 | 2 | $232.64 | $465 |
| 2026-04-29 | 6 | $203.98 | $1K |
| 2026-04-20 | 6 | $203.42 | $1K |
| 2026-04-08 | 20 | $190.94 | $4K |
| 2026-04-07 | 335 | $186.85 | $63K |
| 2026-04-06 | 4 | $186.95 | $748 |
| 2026-03-31 | 4 | $183.15 | $733 |
| 2026-03-27 | 1,695 | $189.15 | $321K |
| 2026-03-23 | 594 | $180.62 | $107K |
| 2026-03-17 | 45 | $182.02 | $8K |
| 2026-03-11 | 51 | $185.93 | $9K |
| 2026-02-13 | 1,782 | $166.29 | $296K |
| 2026-02-05 | 4,788 | $165.72 | $793K |
| 2026-02-04 | 3,832 | $166.84 | $639K |
| 2026-01-27 | 4,791 | $166.35 | $797K |
| 2026-01-20 | 11,128 | $169.41 | $1.9M |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at JAZZ reported 8 open-market sells worth $22.2M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: COZADD BRUCE C on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | COZADD BRUCE C | n/a | Sell | 6K | $250.13 | $1.5M | 352K |
| 2026-08-31 | Kennedy Patrick | n/a | Tax withholding | 2K | $241.39 | $444K | 6K |
| 2026-08-31 | Kennedy Patrick | n/a | Tax withholding | 15 | $244.06 | $4K | 8K |
| 2026-08-31 | Smith Mark Douglas | n/a | Tax withholding | 2K | $241.39 | $408K | 10K |
| 2026-08-31 | Smith Mark Douglas | n/a | Tax withholding | 14 | $244.64 | $3K | 11K |
| 2026-08-31 | McSharry Heather Ann | n/a | Tax withholding | 2K | $241.39 | $444K | 18K |
| 2026-08-31 | McSharry Heather Ann | n/a | Tax withholding | 15 | $244.64 | $4K | 20K |
| 2026-08-31 | Winningham Rick E | n/a | Tax withholding | 14 | $244.64 | $3K | 9K |
| 2026-08-31 | Winningham Rick E | n/a | Tax withholding | 2K | $241.39 | $408K | 9K |
| 2026-08-31 | LOVE TED W | n/a | Tax withholding | 737 | $241.39 | $178K | 2K |
| 2026-08-31 | LOVE TED W | n/a | Tax withholding | 6 | $244.06 | $1K | 3K |
| 2026-08-31 | RIEDEL NORBERT G | n/a | Tax withholding | 2K | $241.39 | $408K | 7K |
| 2026-08-31 | RIEDEL NORBERT G | n/a | Tax withholding | 14 | $244.64 | $3K | 9K |
| 2026-08-31 | Henderson Mary Elizabeth | SVP, Technical Operations | Tax withholding | 16 | $244.64 | $4K | 25K |
| 2026-08-31 | Henderson Mary Elizabeth | SVP, Technical Operations | Tax withholding | 2K | $241.39 | $501K | 25K |
| 2026-08-31 | Hamill Laura | n/a | Tax withholding | 2K | $241.39 | $408K | 7K |
| 2026-08-31 | Hamill Laura | n/a | Tax withholding | 14 | $244.06 | $3K | 9K |
| 2026-08-31 | ENRIGHT PATRICK G | n/a | Tax withholding | 2K | $241.39 | $408K | 21K |
| 2026-08-31 | ENRIGHT PATRICK G | n/a | Tax withholding | 14 | $244.64 | $3K | 23K |
| 2026-08-31 | Cook Jennifer E. | n/a | Tax withholding | 2K | $241.39 | $408K | 11K |
| 2026-08-31 | Cook Jennifer E. | n/a | Tax withholding | 14 | $244.06 | $3K | 12K |
| 2026-08-31 | COZADD BRUCE C | n/a | Tax withholding | 1K | $241.39 | $292K | 358K |
| 2026-08-31 | COZADD BRUCE C | n/a | Tax withholding | 10 | $244.06 | $2K | 359K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 300 | $252.76 | $76K | 66K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 9K | $251.95 | $2.3M | 66K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 20K | $250.60 | $4.9M | 75K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 18K | $250.02 | $4.5M | 95K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 11K | $248.67 | $2.8M | 113K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 18K | $247.86 | $4.5M | 124K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Option exercise | 3K | $137.12 | $400K | 143K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Option exercise | 28K | $137.12 | $3.8M | 140K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Option exercise | 884 | $113.10 | $100K | 112K |
| 2026-08-27 | Iannone Robert | EVP, Global Head of R&D & CMO | Option exercise | 26K | $113.10 | $3.0M | 111K |
| 2026-08-05 | Kennedy Patrick | n/a | Grant | 2K | $0.00 | $0 | 8K |
| 2026-08-05 | Pearce Samantha | EVP, Chief Commercial Officer | Tax withholding | 780 | $261.62 | $204K | 47K |
| 2026-08-05 | Smith Mark Douglas | n/a | Grant | 2K | $0.00 | $0 | 11K |
| 2026-08-05 | McSharry Heather Ann | n/a | Grant | 2K | $0.00 | $0 | 20K |
| 2026-08-05 | Mulligan Seamus | n/a | Grant | 2K | $0.00 | $0 | 1.2M |
| 2026-08-05 | Winningham Rick E | n/a | Grant | 2K | $0.00 | $0 | 11K |
| 2026-08-05 | LOVE TED W | n/a | Grant | 2K | $0.00 | $0 | 3K |
| 2026-08-05 | RIEDEL NORBERT G | n/a | Grant | 2K | $0.00 | $0 | 9K |
| 2026-08-05 | Hamill Laura | n/a | Grant | 2K | $0.00 | $0 | 9K |
| 2026-08-05 | ENRIGHT PATRICK G | n/a | Grant | 2K | $0.00 | $0 | 23K |
| 2026-08-05 | Cook Jennifer E. | n/a | Grant | 2K | $0.00 | $0 | 12K |
| 2026-08-05 | COZADD BRUCE C | n/a | Grant | 2K | $0.00 | $0 | 362K |
| 2026-08-03 | COZADD BRUCE C | n/a | Sell | 6K | $252.98 | $1.5M | 361K |
| 2026-06-03 | GALA RENEE D | President & CEO | Gift | 600 | $0.00 | $0 | 152K |
| 2026-06-01 | COZADD BRUCE C | n/a | Sell | 6K | $235.12 | $1.4M | 373K |
| 2026-05-28 | Pearce Samantha | EVP, Chief Commercial Officer | Sell | 7K | $235.41 | $1.6M | 50K |
| 2026-05-28 | Pearce Samantha | EVP, Chief Commercial Officer | Option exercise | 7K | $109.45 | $756K | 57K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for JAZZ worth $30.3M at the prices reported; 16 in the last 90 days worth $30.3M. Latest: NEENA PATIL filed on 2026-09-10 to sell 1,200 shares ($289K) from 2026-09-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-10 | NEENA PATILOfficer | 1K | $289K | 0.002% | 2026-09-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-08 | Henderson Mary ElizabethDirector | 3K | $664K | 0.004% | 2026-09-08 | ETRADE FINANCIAL CORPORATION |
| 2026-09-08 | RENEE D GALAOfficer | 2K | $486K | 0.003% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-31 | Kennedy PatrickDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | Smith Mark DouglasDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | McSharry Heather AnnDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | Winningham Rick EDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | LOVE TED WDirector | 2K | $373K | 0.002% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | RIEDEL NORBERT GDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | Henderson Mary ElizabethDirector | 4K | $942K | 0.006% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | Hamill LauraDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | ENRIGHT PATRICK GDirector | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | Cook Jennifer E.Director | 4K | $858K | 0.005% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-31 | COZADD BRUCE CDirector | 3K | $613K | 0.004% | 2026-08-31 | ETRADE FINANCIAL CORPORATION |
| 2026-08-27 | ROBERT IANNONEOfficer | 77K | $19.2M | 0.118% | 2026-08-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | ORiordan AnneDirector | 4K | $882K | 0.005% | 2026-08-07 | ETRADE FINANCIAL CORPORATION |
13F holders
Tracked managers holding JAZZ at their latest 13F. JSON7 of the 30 tracked managers held JAZZ at their latest 13F, $1.06B in total at quarter-end prices. AQR Capital Management is the largest at $359.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 1.5M | $359.9M | 0.13% | +184K |
| Citadel Advisors | 2026-06-30 | 1.1M | $261.6M | 0.03% | -258K |
| Millennium Management | 2026-06-30 | 764K | $184.1M | 0.07% | +690K |
| Renaissance Technologies | 2026-06-30 | 562K | $135.4M | 0.19% | -257K |
| Two Sigma Investments | 2026-06-30 | 400K | $96.4M | 0.07% | +381K |
| D. E. Shaw & Co. | 2026-06-30 | 87K | $21.0M | 0.01% | -211K |
| Point72 Asset Management | 2026-06-30 | 8K | $2.0M | 0.00% | -356K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) Jazz Pharmaceuticals plc reported revenue of $1.21B, up 15.5% from the same quarter a year earlier, and net income of $192.8M (2.78 diluted EPS). In FY 2025 it generated $1.36B of operating cash flow and spent $125.0M on buybacks. As of 2026-06-30, cash was $1.62B against $4.35B of debt.
- Cash
- $1.62B
- Debt
- $4.35B
- Equity
- $4.80B
- Total assets
- $11.08B
- Shares outstanding
- 64,914,577
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.21B | $192.8M | 16.0% | 2.78 |
| Q1 2026 | 2026-03-31 | $1.07B | $293.1M | 27.4% | 4.43 |
| Q4 2025derived | 2025-12-31 | $1.20B | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $1.13B | $251.4M | 22.3% | 4.08 |
| Q2 2025 | 2025-06-30 | $1.05B | -$718.5M | -68.7% | -11.74 |
| Q1 2025 | 2025-03-31 | $897.8M | -$92.5M | -10.3% | -1.52 |
| Q4 2024derived | 2024-12-31 | $1.09B | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $1.05B | $215.1M | 20.4% | 3.42 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $4.27B | n/a | $1.36B | $58.8M | $125.0M | n/a |
| FY 2024 | 2024-12-31 | $4.07B | n/a | $1.40B | $38.1M | $311.4M | n/a |
| FY 2023 | 2023-12-31 | $3.83B | n/a | $1.09B | $24.0M | $269.8M | n/a |
| FY 2022 | 2022-12-31 | $3.66B | n/a | $1.27B | $29.0M | $54K | n/a |
| FY 2021 | 2021-12-31 | $3.09B | n/a | $778.5M | $27.6M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Jazz Pharmaceuticals plc in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Jazz Pharmaceuticals plc (JAZZ), SEC CIK 1232524, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-12.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-10.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1232524Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LGNDLIGAND PHARMACEUTICALS INC
- SIONSionna Therapeutics, Inc.
- LQDALiquidia Corp
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- HOWLWerewolf Therapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of JAZZ is sold short?
What is JAZZ's daily short volume?
Does JAZZ have fails to deliver?
Are JAZZ insiders buying or selling?
Have JAZZ insiders filed to sell?
What did JAZZ report last quarter?
Which funds hold JAZZ?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.